Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that the Company and certain selling stockholders intend to offer shares of the Company's common stock in concurrent public offerings. Bovie Medical and the selling stockholders also expect to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Bovie Medical will use the net proceeds from the offering to expand its sales and marketing activities, to expand its research and development efforts, to conduct clinical trials, and for general corporate purposes and working capital. The Company will not receive any proceeds from the sale of common stock by the selling stockholders. Piper Jaffray is acting as sole manager of the offerings. The offerings will be made pursuant to shelf registration statements previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective. A preliminary prospectus supplement has been filed with the SEC for each of the offerings and a final prospectus supplement relating to each offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplements and the accompanying prospectuses, when available, may be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924 or by email: email@example.com This press release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.